AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

François Lux*, Vu Long Tran, Eloïse Thomas, Sandrine Dufort, Fabien Rossetti, Matteo Martini, Charles Truillet, Tristan Doussineau, Guillaume Bort, Franck Denat, Frédéric Boschetti, Goran Angelovski, Alexandre Detappe, Yannick Crémillieux, Nathalie Mignet, Bich-Thuy Doan, Benoit Larrat, Sébastien Meriaux, Emmanuel Barbier, Stéphane RouxPeter Fries, Andreas Müller, Marie-Caline Abadjian, Carolyn Anderson, Emmanuelle Canet-Soulas, Penelope Bouziotis, Muriel Barberi-Heyob, Céline Frochot, Camille Verry, Jacques Balosso, Michael Evans, Jacqueline Sidi-Boumedine, Marc Janier, Karl Butterworth, Stephen McMahon, Kevin Prise, Marie-Thérèse Aloy, Dominique Ardail, Claire Rodriguez-Lafrasse, Erika Porcel, Sandrine Lacombe, Ross Berbeco, Awatef Allouch, Jean-Luc Perfettini, Cyrus Chargari, Eric Deutsch, Géraldine Le Duc, Olivier Tillement

*Corresponding author for this work

Research output: Contribution to journalArticle

15 Citations (Scopus)
254 Downloads (Pure)

Abstract

AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.

Original languageEnglish
Article number20180365
Number of pages19
JournalBritish Journal of Radiology
Volume92
Issue number1093
Early online date18 Sep 2018
DOIs
Publication statusPublished - 01 Jan 2019

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine'. Together they form a unique fingerprint.

  • Cite this

    Lux, F., Tran, V. L., Thomas, E., Dufort, S., Rossetti, F., Martini, M., Truillet, C., Doussineau, T., Bort, G., Denat, F., Boschetti, F., Angelovski, G., Detappe, A., Crémillieux, Y., Mignet, N., Doan, B-T., Larrat, B., Meriaux, S., Barbier, E., ... Tillement, O. (2019). AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, 92(1093), [20180365]. https://doi.org/10.1259/bjr.20180365